Inflammatory bowel disease is treated with a combination of medication, dietary changes, and sometimes surgery, with the specific approach depending on whether you have Crohn’s disease or ulcerative colitis, how severe your symptoms are, and how much of your digestive tract is affected. The treatment landscape has shifted significantly in recent years. Updated 2025 guidelines from the American College of Gastroenterology now recommend that people with moderate-to-severe disease can start advanced therapies right away, rather than working through older, less targeted medications first.
Anti-Inflammatory Medications for Mild to Moderate Disease
For mild to moderate ulcerative colitis, the first-line treatment is a class of drugs called 5-ASAs (the most common being mesalamine). These medications work directly on the lining of the colon to reduce inflammation. Major guidelines recommend at least 2 grams per day for both inducing and maintaining remission, with the optimal dose for getting a moderate flare under control being 4 grams per day. If your disease is limited to the lower colon or rectum, you may also use a topical form (suppository or enema) at 1 gram or more per day, sometimes alongside the oral version.
One important thing about 5-ASAs: they only work if you take them consistently. If you respond well, you can stay on them indefinitely as maintenance therapy. Over time, if your inflammation stays low and your gut lining heals, your doctor may reduce the dose. But skipping doses is one of the most common reasons people relapse.
These medications are primarily effective for ulcerative colitis. Crohn’s disease, which can affect deeper layers of tissue and appear anywhere in the digestive tract, typically requires stronger therapies.
Immune-Modifying Drugs
When inflammation is more widespread or doesn’t respond to 5-ASAs, treatment moves to drugs that broadly dial down immune activity. Corticosteroids (like prednisone) can rapidly control a flare, but they come with significant side effects when used long-term, including bone loss, weight gain, and increased infection risk. They’re strictly short-term tools to bridge the gap while slower-acting therapies take effect.
Immunomodulators such as thiopurines and methotrexate suppress the immune system more broadly and are used to maintain remission. These take weeks to months to reach full effect and require regular blood monitoring. For years, guidelines required patients to try and fail these medications before moving to biologic therapies. That requirement has now been dropped for moderate-to-severe disease.
Biologic Therapies
Biologics are lab-made proteins that target specific parts of the immune response driving intestinal inflammation. They represent the biggest shift in IBD treatment over the past two decades and are now a cornerstone for moderate-to-severe Crohn’s disease and ulcerative colitis. There are several classes, each blocking a different pathway.
Anti-TNF agents were the first biologics approved for IBD and remain widely used. They neutralize a key inflammatory protein (tumor necrosis factor) that drives tissue damage in the gut. Integrin inhibitors take a different approach: they prevent certain immune cells from migrating into the intestinal wall in the first place, which makes them more gut-specific and generally associated with fewer systemic side effects.
The newest class targets interleukins, specifically IL-12 and IL-23, which are signaling molecules that activate inflammatory immune cells. The 2025 ACG guidelines now include several newer IL-23 inhibitors alongside established options like ustekinumab. For patients who have previously tried an anti-TNF drug without success, risankizumab (an IL-23 inhibitor) is now preferred over ustekinumab based on comparative evidence.
Most biologics are given by injection or infusion, typically every two to eight weeks depending on the drug and phase of treatment. Finding the right biologic often involves some trial and error, and it can take several weeks to see the full benefit.
Biosimilars and Cost
Biosimilars are near-identical copies of original biologic drugs, approved through a shorter regulatory pathway once the original’s patent expires. They are just as safe and effective as the originator, with no clinically meaningful differences. Switching from an original biologic to a biosimilar is well-supported by evidence, and the hope is that manufacturing cost savings translate into lower out-of-pocket expenses for patients. If your doctor suggests switching to a biosimilar, it’s a cost decision, not a quality compromise.
Small Molecule Therapies
JAK inhibitors are oral pills that block inflammation at the cellular level, offering an alternative for people who prefer not to take injections or who haven’t responded to biologics. Tofacitinib and upadacitinib are both approved for moderate-to-severe ulcerative colitis. In clinical trials, 59% of patients on tofacitinib maintained or achieved remission at three years. Even among people who didn’t respond after the standard 8-week induction period, 52% achieved a clinical response when given an additional 8 weeks.
About a third of patients on tofacitinib achieved steroid-free remission at one year, which is a meaningful benchmark because it means controlling the disease without the side effects of corticosteroids. JAK inhibitors do carry specific safety considerations, particularly regarding infections and blood clots, so they’re typically reserved for people who need them most.
Early Aggressive Treatment vs. Step-Up
Historically, IBD treatment followed a “step-up” model: start with milder drugs and escalate only when they fail. The problem is that intestinal damage can accumulate while you’re working through less effective options. A growing body of evidence supports starting potent therapy earlier, particularly for Crohn’s disease.
The PROFILE trial compared a top-down approach (starting with biologic therapy plus an immunomodulator) against accelerated step-up treatment in newly diagnosed Crohn’s patients. At 48 weeks, 60% of patients in the top-down group achieved endoscopic remission (no visible ulcers) compared to 45% in the step-up group. The CALM trial showed similar patterns: patients whose treatment was escalated based on objective inflammatory markers rather than symptoms alone had mucosal healing rates of 46% versus 30%.
This is why the 2025 ACG guidelines now explicitly recommend against requiring patients to fail conventional therapies before starting advanced treatments. The evidence shows early intervention with biologics or small molecules leads to better outcomes.
How Doctors Track Your Progress
Treating IBD isn’t just about controlling symptoms. You can feel fine while inflammation silently damages your intestinal lining, so doctors rely on objective markers. One of the most useful is fecal calprotectin, a protein shed by inflamed gut tissue that can be measured with a simple stool test.
In Crohn’s disease, calprotectin levels below roughly 75 micrograms per gram strongly predict clinical remission, while levels around 80 or below correlate with endoscopic remission (meaning the gut lining looks healthy on a scope). For context, people with moderately to severely active disease typically have levels above 400. This test allows your doctor to adjust treatment without necessarily performing a colonoscopy every time, though periodic scoping remains important for assessing healing and screening for precancerous changes.
Dietary Approaches
Diet doesn’t replace medication for most people with IBD, but it can meaningfully reduce symptoms and support remission. The IBD Anti-Inflammatory Diet (IBD-AID), developed at UMass Chan Medical School, is one of the more structured approaches. It eliminates lactose, wheat, refined sugar, corn, processed foods, trans fats, and common food emulsifiers like carrageenan and polysorbate 80 (check ingredient labels for these). Beer is off the list due to grain content. Aged cheeses are allowed, but fresh cheeses and milk are not. Oats are the one grain permitted for most people.
The diet is introduced in phases, starting with soft, well-cooked foods and gradually reintroducing more textures as tolerance improves. The Specific Carbohydrate Diet follows a similar philosophy of eliminating complex carbohydrates that may feed harmful gut bacteria. Neither diet has the large-scale clinical trial data that medications do, but many patients find them helpful as a complement to medical therapy, particularly for managing day-to-day symptoms like bloating, urgency, and diarrhea.
When Surgery Becomes Necessary
Surgery isn’t a failure of treatment. For some people, it’s the most effective path to better quality of life. The indications range from emergencies to planned decisions.
- Emergency surgery is required for life-threatening complications: a perforated colon, uncontrollable bleeding, or toxic megacolon (a dangerous dilation of the colon).
- Urgent surgery applies when severe, acute colitis doesn’t respond to intensive medical treatment in the hospital.
- Elective surgery is considered for persistent symptoms despite medication, increased cancer risk from long-standing disease, or the discovery of precancerous tissue changes on biopsy.
For ulcerative colitis, surgery involves removing the entire colon and rectum. The most common reconstruction connects the small intestine to the anus with an internal pouch, preserving the ability to pass stool normally, though bowel frequency increases. For Crohn’s disease, surgery is more conservative, removing only the damaged segments, because Crohn’s can recur elsewhere in the digestive tract. Many people with Crohn’s will need more than one surgery over their lifetime, which is why preserving as much healthy bowel as possible matters.